Forbes -
21 Sep 2021 14:00

The stock price of BeiGene, a biotechnology company focused on developing molecularly targeted and immuno-oncology drug candidates, has seen a rise of 46% over the last twenty-one trading days, while it is up 54% year-t0-date. The recent rise in the stock can be attributed to the U.S. FDA's...
Share this Article